Arvinas Newsroom

Promising Potential and Strong Efficacy of Arvinas Holding's Vepdeg+Abema Combination Drive Buy Rating

TipRanks05:06 ET · Ratings

The clinical results of the protein degradation combination therapy by Arvinas and Pfizer (PFE.US) are positive, with a clinical benefit rate for patients exceeding 62%.

Arvinas and Pfizer (PFE.US) today announced preliminary data from the ongoing Phase 1b clinical trial TACTIVE-U sub-study.

Zhitong Finance19:13 ET

Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment

MT NewswiresDec 10 10:05 ET

Arvinas and Pfizer Announce Encouraging Preliminary Phase 1b Results for Vepdegestrant Combined With Abemaciclib in Advanced ER+/HER2- Breast Cancer

Quiver QuantitativeDec 10 09:11 ET

Arvinas And Pfizer To Present Initial Phase 1b Data From TACTIVE-U Sub-Study Of Vepdegestrant In Combination With Abemaciclib At 2024 San Antonio Breast Cancer Symposium

BenzingaDec 10 09:09 ET

Express News | Arvinas Inc - Combination Shows Consistent Safety Profile, No Significant Drug Interaction

ReutersDec 10 09:05 ET

Express News | Arvinas Inc - Vepdegestrant and Abemaciclib Show 62.5% Clinical Benefit Rate

ReutersDec 10 09:05 ET

Arvinas and Pfizer Announce Initial Phase 1b Data From the TACTIVE-U Sub-Study of Vepdegestrant in Combination With Abemaciclib at 2024 San Antonio Breast Cancer Symposium

GlobeNewswireDec 10 09:05 ET

Arvinas Initiated With a Buy at BTIG

TipRanksDec 10 07:17 ET · Ratings

Multiple Insiders Sold Arvinas Shares Presenting Weak Signs For Investors

Simply Wall StDec 6 07:37 ET

Piper Sandler Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $67

Moomoo NewsDec 5 11:31 ET · Ratings

Press Release: Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

Dow JonesNov 27 07:00 ET

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

ArvinasNov 27 00:00 ET

BMO Capital Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $88

Moomoo NewsNov 26 08:32 ET · Ratings

Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60

Moomoo NewsNov 26 05:34 ET · Ratings

Positive Outlook for Arvinas Due to Promising Safety Data and Upcoming Developments

TipRanksNov 26 04:56 ET

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

ArvinasNov 25 00:00 ET

Arvinas Holding's VERITAC-2 Trial Progress Drives Buy Rating Despite Adjusted Price Target

TipRanksNov 21 01:16 ET · Ratings

Unveiling 4 Analyst Insights On Arvinas

BenzingaNov 20 10:00 ET

Arvinas Is Maintained at Outperform by BMO Capital

Dow JonesNov 20 09:14 ET · Ratings